Bicycle Therapeutics Announces Presentation of Updated Data from Phase I/IIa Trial Evaluating BT1718 in Patients with Advanced Solid Tumors September 30, 2019
Bicycle Therapeutics Reports Second Quarter 2019 Financial Results and Provides Clinical Update August 12, 2019
Bicycle Therapeutics Announces Positive Topline Results from Oxurion’s Phase I Trial Using a Novel Bicycle-based Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema July 1, 2019
Bicycle Therapeutics Enters Neuroscience Arena through Collaboration with Dementia Discovery Fund May 7, 2019
Bicycle Therapeutics and Oxurion Announce Full Enrollment in Phase I Trial for the Treatment of Diabetic Macular Edema April 24, 2019
